Oil-Dri of America (ODC) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
12 Mar, 2026Executive summary
Delivered strong financial performance in Q2 FY2026, with EBITDA at $22 million and record net sales of $117.7 million, up 1% year-over-year, despite operational disruptions from Winter Storm Fern.
Net sales for the six months ended January 31, 2026, declined 3% year-over-year to $238.2 million, primarily due to softer volumes and weather-related disruptions.
Net income for the quarter was $12.6 million, down 3% year-over-year, and for the six months was $28.0 million, down 4%.
Maintained robust cash position, ending the quarter with $46.9 million in cash and $40 million in debt.
Completed a two-for-one stock split in January 2025, increasing authorized shares and adjusting incentive plans.
Financial highlights
EBITDA for Q2 FY2026 was $22 million, flat year-over-year; quarterly EBITDA was $21.7 million, slightly down from $22.2 million last year.
Gross profit for the quarter was $32.3 million, down 6% year-over-year; gross margin declined to 27.4% from 29.5%.
Operating income for the six months was $32.6 million, a 16% decrease year-over-year.
Cash and cash equivalents at quarter-end were $46.9 million, with debt at $40 million.
Net cash provided by operating activities for the six months was $28.4 million.
Outlook and guidance
Management expects to surpass last year's annual net income if current trends continue.
Expect continued strong performance in agriculture and horticulture segments, with bullish outlook for growth.
Anticipate new product launches in the second half of the fiscal year to support strategic growth.
Management expects sufficient liquidity for foreseeable working capital, capital expenditures, dividends, and debt service.
Remain optimistic about long-term prospects for Amlan and animal nutrition markets despite recent account loss.
Latest events from Oil-Dri of America
- Record net income and Ultra Pet acquisition drive growth, with margin and sales gains.ODC
Q3 20241 Feb 2026 - Record sales, margin expansion, and Ultra Pet integration drive strong growth outlook.ODC
Q4 202419 Jan 2026 - Record sales, profit, and margin expansion driven by Ultra Pet and high-value segment growth.ODC
Q1 202511 Jan 2026 - Record FY2025 results with double-digit growth, strong cash flow, and a positive FY2026 outlook.ODC
Q4 20257 Jan 2026 - Record sales, margin expansion, and robust B2B and animal health growth in Q2.ODC
Q2 202526 Dec 2025 - Record results in 2025 and strong Q1 FY2026 earnings drive continued growth and investment.ODC
Q1 2026 & AGM 20259 Dec 2025 - Virtual meeting to elect directors, ratify auditor, and approve stock split amid strong governance focus.ODC
Proxy Filing1 Dec 2025 - Key votes include director elections, auditor ratification, and a 2:1 stock split approval.ODC
Proxy Filing1 Dec 2025 - Virtual meeting to elect nine directors, ratify auditor, and highlight ESG and governance priorities.ODC
Proxy Filing1 Dec 2025